Evommune (EVMN) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, targeting conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

• Pipeline includes two Phase 2 product candidates, EVO756 and EVO301, with expansion potential into additional indications.

• EVO756 is a selective oral small molecule antagonist of MRGPRX2, aiming to modulate neuroimmune interactions for rapid symptom relief.

• Mission centers on improving patient quality of life and preventing long-term effects of uncontrolled inflammation.

Financial performance and metrics

• Completed a private placement in February 2026, raising gross proceeds of approximately $125.3 million from the sale of Series C Preferred Stock and common stock.

• IPO in November 2025 raised $172.5 million through the sale of 10,781,250 shares at $16.00 per share.

• As of March 31, 2026, 36,018,372 shares of common stock were outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from prior private placements and IPO are allocated to business development and growth.

• Intends to retain all future earnings to fund development and growth; no plans to pay dividends in the foreseeable future.